title: Topical linezolid 0.2% for the treatment of vancomycin-resistant or vancomycin-intolerant gram-positive bacterial keratitis.
abstract: OBJECTIVE
  To report the successful use of topical linezolid 0.2% in the treatment of gram-positive bacterial keratitis.
  
  
  METHODS
  Retrospective, interventional case series.
  
  
  METHODS
  All cases of bacterial keratitis treated at the University of Illinois Eye and Ear Infirmary with topical linezolid were identified from the Cornea and External Disease Clinic and were reviewed for culture results, prior therapy, clinical course, and visual outcome.
  
  
  RESULTS
  Three patients received topical linezolid, all for cases of culture-positive or presumed gram-positive keratitis. Cases consisted of 1 patient with recalcitrant vancomycin-resistant Enterococcus faecalis (VRE) and 2 patients with infectious crystalline keratitis, 1 previously culture-positive for an uncharacterized Staphylococcus and the other for Streptococcus mitis. All 3 patients had rapid resolution of their infectious keratitis and noted no pain or discomfort attributed to the topical therapy. The patient with VRE keratitis developed a consecutive Candida keratitis elsewhere in the same cornea at the end of therapy for her VRE keratitis.
  
  
  CONCLUSIONS
  Topical linezolid 0.2% can be an effective ophthalmic antibiotic for the treatment of gram-positive keratitis, including VRE, and is both significantly more comfortable and less immediately toxic to the ocular surface than topical vancomycin.
authors: Department of Ophthalmology and Visual Sciences, University of Illinois Eye and Ear Infirmary, Chicago, Illinois, USA. etu@uic.edu
authors: Elmer Yuchen
authors: EY
authors: Tu
authors: Sandeep
authors: S
authors: Jain
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D013293:Enterococcus faecalis / Q000187:drug effects / Q000302:isolation & purification; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D023303:Oxazolidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D034361:Streptococcus mitis / Q000187:drug effects / Q000302:isolation & purification; D020713:Vancomycin Resistance
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D009883:Ophthalmic Solutions; D023303:Oxazolidinones; D000069349:Linezolid